You are here
L2 DIAGNOSTICS LLC
UEI: GKA7VH5LFR25
# of Employees: 15
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Protection Against West Nile Virus by RNA Interference
Amount: $713,641.00DESCRIPTION (provided by applicant): West Nile (WN) virus is a flavivirus that can cause fatal human encephalitis. Over the past four years, this virus has established itself across the United States. ...
STTRPhase I2005Department of Health and Human Services National Institutes of Health -
Protection Against West Nile Virus by RNA Interference
Amount: $713,641.00DESCRIPTION (provided by applicant): West Nile (WN) virus is a flavivirus that can cause fatal human encephalitis. Over the past four years, this virus has established itself across the United States. ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
Virulence Typing of Pseudomonas Clinical Isolates
Amount: $767,447.00DESCRIPTION (provided by applicant): Pseudomonas aeruginosa is an opportunistic bacterial pathogen responsible for a significant proportion of serious hospital acquired infections. The organism has i ...
SBIRPhase II2005Department of Health and Human Services National Institutes of Health -
Modified HER-2 Tumor Antigens for Vaccination in Cancer
Amount: $99,899.00DESCRIPTION (provided by applicant): The proposed studies are aimed at developing a new tumor immunotherapy by using isoaspartyl-modified peptides to break immune tolerance to "self" tumor antigens on ...
STTRPhase I2004Department of Health and Human Services National Institutes of Health -
Isoaspartyl Modified Tumor Antigens for Vaccination
Amount: $99,829.00DESCRIPTION (provided by applicant): This proposal will take advantage of several unique observations made in understanding the properties of self proteins that regulate the development of autoimmune ...
STTRPhase I2004Department of Health and Human Services National Institutes of Health -
Virulence Typing of Pseudomonas Clinical Isolates
Amount: $99,963.00DESCRIPTION (provided by applicant): Pseudomonas aeruginosa is an opportunistic bacterial pathogen responsible for a significant proportion of serious hospital acquired infections. The organism has i ...
STTRPhase I2004Department of Health and Human Services National Institutes of Health -
Preclinical development of the tsetse thrombin inhibitor
Amount: $98,179.00DESCRIPTION (provided by applicant): Thromboembolic disease is a major cause of morbidity and mortality in the developed world. Despite the need for effective therapies for treating and preventing pat ...
STTRPhase I2004Department of Health and Human Services National Institutes of Health -
Antibody Prophylaxis and Therapy of Flavivirus Infection
Amount: $969,452.00DESCRIPTION (provided by applicant): The overall goal of this project is to develop antibody therapy and prophylaxis to treat and prevent life-threatening flavivirus infections. West Nile virus is th ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
Modified HER-2 Tumor Antigens for Vaccination in Cancer
Amount: $99,899.00DESCRIPTION (provided by applicant): The proposed studies are aimed at developing a new tumor immunotherapy by using isoaspartyl-modified peptides to break immune tolerance to "self" tumor antigens on ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
Virulence Typing of Pseudomonas Clinical Isolates
Amount: $99,963.00DESCRIPTION (provided by applicant): Pseudomonas aeruginosa is an opportunistic bacterial pathogen responsible for a significant proportion of serious hospital acquired infections. The organism has i ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health
